Propanc Biopharma, Inc.

Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing a new method to prevent the recurrence and spread of solid tumors. The company utilizes pancreatic proenzymes to target and eliminate cancer stem cells in patients with pancreatic, ovarian, and colorectal cancers. This proenzyme therapy is based on the scientific principle that enzymes, particularly those secreted by the pancreas, stimulate biological reactions and may serve as the body's primary defense against cancer. Propanc's main product candidate is PRP, a novel formulation involving proenzymes, which are inactive precursors of enzymes. The company has conducted successful pre-clinical studies on PRP, showing positive early indications of its anti-cancer effects. Subject to securing sufficient financing, Propanc plans to begin preparing its Investigational Medicinal Product Dossier, study proposal, and Investigator's Brochure in 2025. The company then intends to start its study preparation process, including selecting a contract research organization (CRO), analytical lab, and trial sites, and to begin compiling its clinical trial application for PRP (CTA) in the first calendar quarter of 2026. The goal is to complete and submit the CTA in the first half of the 2026 calendar year. In the second calendar quarter of 2026, Propanc plans to initiate logistics and trial site initiation visits.